The Technical Analyst
Tekla Life Sciences [HQL]
Exchange: NYSE Sector: Financial Services Industry: Asset Management
Tekla Life Sciences Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.40% $13.75
America/New_York / 9 mai 2024 @ 09:54
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 376.19 mill |
| EPS: | 0.790 |
| P/E: | 17.41 |
| Earnings Date: | Jun 03, 2024 |
| SharesOutstanding: | 27.35 mill |
| Avg Daily Volume: | 0.0911 mill |
| RATING 2024-05-08 |
|---|
| C- |
| Strong Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Strong Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 1/22 | 2/22 | 3/22 | 4/22 | 1/23 | 3/23 | |
| Revenue | n/a | n/a | n/a | |||
| Gr.Profit | n/a | n/a | n/a | |||
| Ebit | n/a | n/a | n/a | |||
| Asset | n/a | n/a | ||||
| Debt | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 1.76x |
| Company: PE 17.41 | sector: PE 9.91 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.87x |
| Company: PE 17.41 | industry: PE 20.04 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.0000 (-100.00%) $-13.75 |
| Date: 2024-05-09 |
| Expected Trading Range (DAY) |
|---|
|
$ 13.60 - 13.92 ( +/- 1.19%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-05-07 | Saba Capital Management, L.p. | Buy | 50 161 | Common Stock |
| 2024-05-06 | Saba Capital Management, L.p. | Buy | 10 713 | Common Stock |
| 2024-05-02 | Saba Capital Management, L.p. | Buy | 26 274 | Common Stock |
| 2024-05-01 | Saba Capital Management, L.p. | Buy | 252 | Common Stock |
| 2024-04-30 | Saba Capital Management, L.p. | Buy | 16 573 | Common Stock |
| INSIDER POWER |
|---|
| 100.00 |
| Last 62 transactions |
| Buy: 641 823 | Sell: 55 759 |
Forecast:
11:35 - $13.69
Live Trading Signals (every 1 min)
Forecast
1: 10:05 - $13.77
Forecast 2: 10:55 - $13.72
Forecast 3: 11:35 - $13.69
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $13.75 (0.40% ) |
| Volume | 0.0036 mill |
| Avg. Vol. | 0.0911 mill |
| % of Avg. Vol | 3.97 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For HQL
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
HQL
Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. It was formerly known as H&Q Life Sciences Investors fund. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.
Latest Press Releases
2024-03-21 07:59:00 - Press Release
Abrdn Healthcare Investors (hqh), Abrdn Life Sciences Investors (hql), Abrdn healthcare Opportunities Fund (thq), And Abrdn World Healthcare Fund (thw) Announce Investment Team Update
Philadelphia, pa / accesswire / march 21, 2024 / abrdn healthcare investors (nyse:hqh), abrdn life sciences investors (nyse:hql), abrdn healthcare opportunities fund (nyse:thq), and abrdn world healthcare fund (nyse:thw) (collectively, the "funds") each, a closed-end management investment company, announced today the appointment of dr. jason akus as co-lead portfolio manager to the funds alongside dr. daniel omstead. dr. akus has served on the investment team with dr. omstead for over 20 years.
2023-11-09 16:27:00 - Press Release
Abrdn U.s. Closed-end Funds Announce Distribution Payment Details
Philadelphia, pa / accesswire / november 9, 2023 / the following abrdn u.s. closed-end funds announced today that the closed end funds in the chart directly below will pay the distributions indicated on a per share basis on november 30, 2023 to all shareholders of record as of november 22, 2023 (ex-dividend date november 21, 2023). these dates apply to the funds listed below with the exception of abrdn healthcare investors (hqh), abrdn life sciences investors (hql), the abrdn australia equity fund, inc. (iaf), the india fund, inc. (ifn) and the abrdn japan equity fund, inc. (jeq) which will pay on january 10, 2024, to all shareholders of record as of november 22, 2023 (ex-dividend date november 21, 2023).
2023-10-27 17:20:00 - Press Release
Abrdn Announces Its Appointment To Four U.s. Specialist Healthcare Closed-end Funds, New Board Of Trustees To The Funds And Fund Name Changes
Philadelphia, pa / accesswire / october 27, 2023 / effective close of business today, october 27, 2023, abrdn inc. ("abrdn") assumed responsibility for the management of the four (4) former tekla capital management llc closed-end funds totaling $2.8bn in assets under management (aum) as of october 26, 2023. as noted within the funds' proxy statements and in connection with the change in investment adviser, each fund amended its declaration of trust to change its name as detailed in the chart below effective after close of regular business on october 27, 2023.
2023-10-27 16:57:00 - Press Release
Tekla Funds Approve New Investment Advisory Agreements With Abrdn Inc.
Boston--(business wire)--tekla capital management llc (tekla) announced today that the requisite vote has been attained to approve the new investment advisory agreement with abrdn inc. for each of its four closed-end funds (the funds). the funds are: tekla healthcare investors (hqh) tekla life sciences investors (hql) tekla healthcare opportunities fund (thq) tekla world healthcare fund (thw) tekla healthcare opportunities fund (thq) and tekla world healthcare fund (thw) approved the proposal a.
2023-10-27 16:57:00 - Press Release
Tekla Capital Management Llc Announces Closing Of Transaction With Abrdn
Tekla capital management llc (tekla) announced today that it has completed the sale of its advisory business to abrdn inc. in addition, effective close of regular business, abrdn was approved as manager to four nyse listed healthcare and biotech thematic closed-end funds, totaling $2.8 bn in assets under management (aum) as of october 26, 2023.
Latest News
2024-01-10 18:30:29 - Seeking Alpha
The Month In Closed-End Funds: December 2023
For the second consecutive month, both equity (+3.42% on a NAV basis) and fixed income (+3.14%) CEFs on average posted plus-side returns. At month end, 9% of all CEFs traded at a premium to their NAV, with 9% of equity CEFs and 8% of fixed income CEFs trading in premium territory. Developed Markets CEFs (+6.45%), for the second straight month, outpaced the other classifications in the equity CEF universe for December.
2023-09-27 14:34:01 - Seeking Alpha
HQL: Hold Your Investments In This Healthcare CEF For Strong, Steady Yield
Tekla Life Sciences Investors invests primarily in biotechnology stocks, and 10-12 large-cap biotech stocks (50% of total holdings) sets the trend and price direction for this fund. Poor price growth of biotech stocks thus has resulted in a huge price loss for this fund. However, the HQL closed-end fund has delivered consistent strong yields over the years. Despite poor price growth, I am bullish about the biotech sector due to aging demographics, adoption of new medical products, and robust M&A activities.
2023-06-29 08:06:53 - Seeking Alpha
HQL: 13% Discount Creates An Opportunity
Tekla Life Sciences Investors is a closed-ended equity fund that primarily invests in the life sciences sector, with a heavy focus on biotech and pharmaceuticals.
2023-03-08 03:27:02 - Seeking Alpha
HQL: Boom-Bust Returns May Not Be Suitable For High Distribution Yield
HQL focuses on the life sciences industry with a 74% allocation to biotechnology stocks. It pays a 2% quarterly managed distribution.
2023-01-09 12:29:04 - Seeking Alpha
Equity CEFs: Top Picks For 2023
2022 was a year to forget, while most believe 2023 will begin with the same issues that took the equity and bond markets well into bear market territory last year. That is, a hawkish Federal Reserve that doesn't want to let up on strangling inflation into submission while draining market liquidity.
2022-12-14 09:30:00 - Seeking Alpha
5 Best CEFs To Buy This Month (December 2022)
For income investors, closed-end funds remain an attractive investment class that covers a variety of asset classes and promises high distributions and reasonable total returns. Closed-end funds are generally characterized by higher volatility and deeper drawdowns than the broad market. For these reasons, they are not suited for everyone.
2022-12-08 10:36:37 - Seeking Alpha
Equity CEFs: What's Going On With Tekla's HQH And HQL?
The iShares Biotechnology ETF (IBB) is down -12.9% year-to-date but the Tekla biotech equity CEFs are down even more despite NAVs that are holding up extremely well. The result is that the Tekla biotech CEFs (HQH) and (HQL) keep dropping to lower-and-lower valuations with HQH now at a -11.6% discount and HQL at a -12.0% discount.
2022-10-23 08:39:54 - Seeking Alpha
Tekla Life Sciences Investors: 10% Yield And Trading 10.5% Below NAV
Tekla Life Sciences currently has a high 10% yield. The CEF is currently trading 10.5% below NAV, providing a better entry point.
2022-07-12 16:47:09 - Seeking Alpha
HQL: A Biotechnology Equity CEF With No Leverage
Tekla Life Sciences Investors is a closed-end fund focused on biotechnology and pharmaceutical stocks. The fund does not employ leverage and has an annualized 5-year total return of only 2.3% while its 10-year range annualized return sits at 9.8%.
2022-04-27 14:38:36 - Seeking Alpha
HQL: Buy For The Yield, If You Can Stomach The Depreciation
HQL pays regular quarterly dividends with a close to double-digit yield, and despite poor price growth over medium and long run, HQL's total return is impressive. In the past three months, a dividend cut and extension of buyback period played a significant role in price movement of HQL.